Exscientia PLCNASDAQ:EXAI
- LAST PRICE5.0700
- TODAY'S CHANGE (%)0.0400 (0.7952%)
- Bid / Lots5.0600/ 5
- Ask / Lots5.1100/ 4
- Open / Previous Close5.1100 / 5.0300
- Day Range
- 52 Week Range
- Volume424,546
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EXAI |
|---|---|---|
| 09:32 ET | 83148 | 5.045 |
| 09:34 ET | 2498 | 5.09 |
| 09:36 ET | 826 | 5.09 |
| 09:38 ET | 4420 | 5.1496 |
| 09:39 ET | 78947 | 5.1192 |
| 09:41 ET | 14855 | 5.015 |
| 09:43 ET | 200 | 5.02 |
| 09:48 ET | 4184 | 5.0399 |
| 09:50 ET | 4188 | 5.02 |
| 09:52 ET | 200 | 5.04 |
| 09:54 ET | 4424 | 5.07 |
| 09:56 ET | 626 | 5.03 |
| 09:57 ET | 4580 | 5.06 |
| 09:59 ET | 100 | 5.06 |
| 10:01 ET | 2644 | 5.055 |
| 10:03 ET | 4552 | 5.0485 |
| 10:08 ET | 2417 | 5.0384 |
| 10:10 ET | 270 | 5.0399 |
| 10:12 ET | 200 | 5.0497 |
| 10:14 ET | 8500 | 5.05 |
| 10:15 ET | 3484 | 5.065 |
| 10:17 ET | 630 | 5.0799 |
| 10:19 ET | 1326 | 5.07 |
| 10:21 ET | 1200 | 5.0935 |
| 10:24 ET | 350 | 5.1199 |
| 10:26 ET | 1200 | 5.12 |
| 10:28 ET | 2463 | 5.13 |
| 10:30 ET | 500 | 5.11 |
| 10:32 ET | 2400 | 5.138 |
| 10:33 ET | 450 | 5.13 |
| 10:35 ET | 1700 | 5.16 |
| 10:37 ET | 1300 | 5.169 |
| 10:39 ET | 10619 | 5.14 |
| 10:42 ET | 1049 | 5.155 |
| 10:44 ET | 1400 | 5.1691 |
| 10:46 ET | 1097 | 5.1687 |
| 10:48 ET | 957 | 5.17 |
| 10:50 ET | 600 | 5.15 |
| 10:51 ET | 400 | 5.179 |
| 10:53 ET | 700 | 5.1611 |
| 10:55 ET | 77131 | 5.18 |
| 10:57 ET | 27731 | 5.21 |
| 11:00 ET | 1144 | 5.1875 |
| 11:02 ET | 600 | 5.17 |
| 11:04 ET | 200 | 5.15 |
| 11:06 ET | 5802 | 5.195 |
| 11:08 ET | 2997 | 5.16 |
| 11:09 ET | 100 | 5.165 |
| 11:11 ET | 5528 | 5.14 |
| 11:13 ET | 5274 | 5.14 |
| 11:15 ET | 2073 | 5.11 |
| 11:18 ET | 100 | 5.1 |
| 11:20 ET | 2713 | 5.07 |
Today
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAI, from 3 minutes ago by Dow Jones
3 minutes ago by Dow JonesSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia, from 24 minutes ago by Dow Jones
24 minutes ago by Dow JonesShareholders of Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI, from 32 minutes ago by Dow Jones
32 minutes ago by Dow JonesEXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm, from 44 minutes ago by Dow Jones
44 minutes ago by Dow JonesShareholders of Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI, from 48 minutes ago by Dow Jones
48 minutes ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exscientia PLC | 436.2M | -3.9x | --- |
OmniAb Inc | 496.3M | -6.6x | --- |
Cartesian Therapeutics Inc | 485.7M | -0.5x | --- |
Arbutus Biopharma Corp | 592.6M | -7.1x | --- |
Iteos Therapeutics Inc | 586.3M | -4.1x | --- |
Applied Therapeutics Inc | 577.1M | -2.6x | --- |
Company Information
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing, and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Patient-first AI, Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company’s advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
Contact Information
- Headquarters
- The Schrodinger Building Oxford Science ParkOXFORD, United Kingdom OX4 4GE
- Phone
- 186-581-8941
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Nicholson
- Interim Chief Executive Officer, Chief Scientific Officer
- David Hallett
- Chief Financial and Strategy Officer, Director
- Ben Taylor
- Chief Technology Officer
- John Overington
- Interim Chief Medical Officer
- Maria-louise Fjaellskog
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $436.2M |
|---|---|
Revenue (TTM) | $24.9M |
Shares Outstanding | 86.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.30 |
Book Value | $3.59 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 17.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -802.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
